1型糖尿病肾脏肾小管功能生物标志物的纵向轨迹
在DCCT/EDIC研究的220例1型糖尿病患者中,跨26年7个时间点测量肾小管生物标志物,发现KIM-1、sTNFR1、MCP1等显著变化,高血糖与sTNFR1和KIM-1的更大增幅相关。
要点
- 1型糖尿病病程中肾小管生物标志物呈显著纵向变化。
- 强化降糖可减缓sTNFR1的升高。
- HbA1c越高,sTNFR1和KIM-1升高越快。
核心结论
- 在基线eGFR正常的1型糖尿病患者中,肾脏肾小管生物标志物在长期随访中显著变化。
- 高血糖与血清或血浆sTNFR1和KIM-1的纵向更大增幅相关。
研究设计与样本
- DCCT/EDIC研究中1型糖尿病队列,选取220例参与者,跨26年7个时间点测量生物标志物。
- 测量包括血清或血浆KIM-1、sTNFR1,定时尿EGF、MCP1及复合肾小管分泌评分。
主要发现
- 基线平均年龄28岁,女性45%,50%被分配至强化降糖治疗。
- 基线平均eGFR为125 ml/min per 1.73 m2,90%参与者尿白蛋白排泄率<30 mg/24h。
- 生物标志物平均变化(百分比/十年):KIM-1 27.3%(95%CI 21.4-33.5),sTNFR1 16.9%(14.5-19.3),MCP1 18.4%(8.9-28.8),EGF -13.5%(-16.7至-10.1),EGF-MCP1比值 -26.9%(-32.2至-21.3),肾小管分泌评分 -0.9%(-1.8至0.0)。
- eGFR变化为-12.0%(95%CI -12.9至-11.1),AER变化为10.9%(2.5-20.1)。
- 强化vs常规降糖与sTNFR1升高较慢相关(变化相对差异0.94[0.90-0.98]);HbA1c每高1%,sTNFR1变化相对差异1.06(1.05-1.08),KIM-1变化相对差异1.09(1.05-1.14)。
临床怎么用
- 在1型糖尿病长期管理中,可关注肾小管生物标志物如sTNFR1和KIM-1的纵向变化。
- 强化降糖可能有助于减缓sTNFR1的升高。
局限性
- 生物标志物仅在220例参与者的子集中测量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Tubular biomarkers may shed insight into progression of kidney tubulointerstitial pathology complementary to traditional measures of glomerular function and damage. METHODS: We examined trajectories of tubular biomarkers in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC Study) of type 1 diabetes (T1D). Biomarkers were measured in a subset of 220 participants across 7 time points over 26 years. Measurements included the following: kidney injury molecule 1 (KIM-1), soluble tumor necrosis factor 1 (sTNFR1) in serum or plasma, epidermal growth factor (EGF), monocyte chemoattractant protein-1 (MCP1) in timed urine, and a composite tubular secretion score. We described biomarker trajectories and examined how these were affected by intensive glucose-lowering therapy and glycemia. RESULTS: At baseline, participants had a mean age of 28 years, 45% were women, and 50% were assigned to intensive glucose-lowering therapy. The mean estimated glomerular filtration rate (eGFR) was 125 ml/min per 1.73 m2 and 90% of participants had a urinary albumin excretion rate (AER) <30 mg/24h. Mean changes in biomarkers over time (percent/decade) were: KIM-1: 27.3% (95% confidence interval [CI]: 21.4-33.5), sTNFR1: 16.9% (14.5-19.3), MCP1: 18.4% (8.9-28.8), EGF: -13.5% (-16.7 to -10.1), EGF-MCP1 ratio: -26.9% (-32.2 to -21.3), and tubular secretion score -0.9% (-1.8 to 0.0), versus -12.0% (CI: -12.9 to -11.1) for eGFR and 10.9% (2.5-20.1) for AER. Intensive versus conventional glucose-lowering therapy was associated with slower increase in sTNFR1 (relative difference in change: 0.94 [0.90-0.98]). Higher HbA1c was associated with faster increases in sTNFR1 (relative difference in change: 1.06 per 1% higher HbA1c [1.05-1.08]) and KIM-1 (1.09 [1.05-1.14]). CONCLUSION: Among participants with T1D and normal eGFR at baseline, kidney tubular biomarkers changed significantly over long-term follow-up. Hyperglycemia was associated with larger increases in serum or plasma sTNFR1 and KIM-1, when followed-up longitudinally.
引用
- Limonte CP, Gao X, Bebu I, et al. Longitudinal Trajectories of Biomarkers of Kidney Tubular Function in Type 1 Diabetes. Kidney Int Rep. 2024. PMID: 38707816. doi:10.1016/j.ekir.2023.11.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。